Literature DB >> 11600379

Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

I Raad1, R Hachem, H Hanna, E Girgawy, K Rolston, E Whimbey, R Husni, G Bodey.   

Abstract

Between February 1994 and November 1998, 56 oncology patients infected with vancomycin-resistant enterococci (VRE) were treated with quinopristin-dalfopristin (Q-D) plus minocycline (MIN). Infections included bacteremia, urinary tract infection, pneumonia, and wound infection. The response rate was 68%, and the most frequent adverse event was arthralgia or myalgia (36%). Q-D-MIN is effective for VRE infection in cancer patients but is associated with a substantial frequency of arthralgia or myalgia.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11600379      PMCID： PMC90805          DOI： 10.1128/AAC.45.11.3202-3204.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).

Authors:  S A McNeil; N M Clark; P H Chandrasekar; C A Kauffman
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

2.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus.

Authors:  R A Howe; M Robson; A Oakhill; J M Cornish; M R Millar
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.

Authors:  M W Griswold; B M Lomaestro; L L Briceland
Journal:  Am J Health Syst Pharm       Date:  1996-09-01       Impact factor: 2.637

5.  Analysis of the resistance mediated by several R-factors to tetracycline and minocycline.

Authors:  J M Robertson; E C Reeve
Journal:  Genet Res       Date:  1972-10       Impact factor: 1.588

6.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

7.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

Authors:  R C Moellering; P K Linden; J Reinhardt; E A Blumberg; F Bompart; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

8.  A semiquantitative culture method for identifying intravenous-catheter-related infection.

Authors:  D G Maki; C E Weise; H W Sarafin
Journal:  N Engl J Med       Date:  1977-06-09       Impact factor: 91.245

9.  Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

Authors:  A H Norris; J P Reilly; P H Edelstein; P J Brennan; M G Schuster
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

10.  How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?

Authors:  I I Raad; D Abi-Said; K V Rolston; C L Karl; G P Bodey
Journal:  Cancer       Date:  1998-06-15       Impact factor: 6.860
View more
  5 in total

1.  Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.

Authors:  Issam I Raad; Hend A Hanna; Ray Y Hachem; Tanya Dvorak; Rebecca B Arbuckle; Gassan Chaiban; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm.

Authors:  Issam I Raad; Hend A Hanna; Maha Boktour; Gassan Chaiban; Ray Y Hachem; Tanya Dvorak; Russell Lewis; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

5.  Composition and dynamics of the respiratory tract microbiome in intubated patients.

Authors:  Brendan J Kelly; Ize Imai; Kyle Bittinger; Alice Laughlin; Barry D Fuchs; Frederic D Bushman; Ronald G Collman
Journal:  Microbiome       Date:  2016-02-11       Impact factor: 14.650
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.